Enliven Therapeutics (ELVN) Competitors $16.77 -0.16 (-0.95%) Closing price 04:00 PM EasternExtended Trading$16.77 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. PTCT, SRPT, RNA, SWTX, RARE, AKRO, ACLX, ZLAB, CRNX, and VKTXShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Arcellx (ACLX), Zai Lab (ZLAB), Crinetics Pharmaceuticals (CRNX), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. PTC Therapeutics Sarepta Therapeutics Avidity Biosciences SpringWorks Therapeutics Ultragenyx Pharmaceutical Akero Therapeutics Arcellx Zai Lab Crinetics Pharmaceuticals Viking Therapeutics Enliven Therapeutics (NASDAQ:ELVN) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment. Is ELVN or PTCT more profitable? Enliven Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.46% -27.33% PTC Therapeutics -50.32%N/A -16.44% Does the MarketBeat Community prefer ELVN or PTCT? PTC Therapeutics received 564 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 92.86% of users gave Enliven Therapeutics an outperform vote while only 62.11% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformEnliven TherapeuticsOutperform Votes1392.86% Underperform Votes17.14%PTC TherapeuticsOutperform Votes57762.11% Underperform Votes35237.89% Does the media refer more to ELVN or PTCT? In the previous week, Enliven Therapeutics had 7 more articles in the media than PTC Therapeutics. MarketBeat recorded 23 mentions for Enliven Therapeutics and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.78 beat Enliven Therapeutics' score of 0.40 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral PTC Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of ELVN or PTCT? 95.1% of Enliven Therapeutics shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher earnings and valuation, ELVN or PTCT? Enliven Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$71.58M-$1.92-8.73PTC Therapeutics$1.77B2.04-$626.60M$6.516.99 Which has more risk and volatility, ELVN or PTCT? Enliven Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Do analysts rate ELVN or PTCT? Enliven Therapeutics currently has a consensus price target of $37.25, indicating a potential upside of 122.12%. PTC Therapeutics has a consensus price target of $63.25, indicating a potential upside of 38.95%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Enliven Therapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20PTC Therapeutics 1 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.64 SummaryEnliven Therapeutics beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$822.89M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-8.839.0626.7119.71Price / SalesN/A251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book2.816.456.774.50Net Income-$71.58M$143.98M$3.23B$248.22M7 Day Performance-5.89%2.41%1.80%0.56%1 Month Performance-6.68%4.56%11.10%13.17%1 Year Performance-26.74%-2.67%17.11%7.30% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.4834 of 5 stars$16.77-0.9%$37.25+122.1%-26.1%$822.89MN/A-8.8350News CoverageAnalyst RevisionPTCTPTC Therapeutics4.1848 of 5 stars$46.01+4.0%$61.92+34.6%+18.9%$3.65B$1.77B-7.751,410Gap UpSRPTSarepta Therapeutics4.8153 of 5 stars$36.37+0.3%$131.22+260.8%-69.0%$3.57B$2.23B29.10840Positive NewsAnalyst ForecastHigh Trading VolumeRNAAvidity Biosciences1.9199 of 5 stars$29.33+5.2%$66.38+126.3%+3.8%$3.53B$10.90M-10.18190Options VolumeSWTXSpringWorks Therapeutics2.3665 of 5 stars$46.12-0.3%$52.57+14.0%+7.5%$3.46B$191.59M-13.25230High Trading VolumeRAREUltragenyx Pharmaceutical3.9707 of 5 stars$36.09+2.8%$90.93+152.0%-12.7%$3.32B$590.69M-5.691,310Positive NewsAKROAkero Therapeutics3.8137 of 5 stars$41.53+4.2%$76.29+83.7%+138.9%$3.31BN/A-11.0730Insider TradeHigh Trading VolumeACLXArcellx1.6399 of 5 stars$59.50+3.4%$109.31+83.7%+23.0%$3.28B$76.81M-83.8080ZLABZai Lab2.6281 of 5 stars$29.40+0.5%$47.37+61.1%+62.9%$3.24B$418.33M-10.611,950CRNXCrinetics Pharmaceuticals3.5526 of 5 stars$33.32+8.6%$73.00+119.1%-39.5%$3.12B$1.04M-8.93210Gap UpVKTXViking Therapeutics4.4222 of 5 stars$28.30+2.7%$87.15+208.0%-57.6%$3.09BN/A-28.3020Positive News Related Companies and Tools Related Companies PTC Therapeutics Competitors Sarepta Therapeutics Competitors Avidity Biosciences Competitors SpringWorks Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Akero Therapeutics Competitors Arcellx Competitors Zai Lab Competitors Crinetics Pharmaceuticals Competitors Viking Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.